Glutathione vs SLU-PP-915

Immune

Metabolic

Research Only

Research Only

Glutathione cycles between reduced (GSH) and oxidized (GSSG) forms, donating electrons to reactive oxygen species via glutathione peroxidase. It serves as a cofactor for glutathione S-transferases (GSTs) in Phase II detoxification, maintains reduced protein thiols, supports T-cell proliferation and NK cell cytotoxicity, and regenerates vitamins C and E. Proposed skin-lightening activity is attributed to inhibition of tyrosinase and a shift from eumelanin toward phaeomelanin synthesis, though clinical evidence is limited and largely from small Asian dermatology trials.

The estrogen-related receptors (ERRα/β/γ) are orphan nuclear receptors that act as master transcriptional regulators of oxidative metabolism, driving mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation, and the TCA cycle — largely as partners of the PGC-1 coactivators. SLU-PP-915 binds and activates all three ERR isoforms with an EC50 of roughly 400 nM at each. In its medicinal-chemistry design, the phenol and aniline groups of earlier ERR agonists were replaced with a boronic-acid moiety on a disubstituted thiophene scaffold, which preserved receptor activity while improving microsomal metabolic stability and oral exposure. In cells and in rodents it upregulates canonical ERR target genes including PGC-1α, lactate dehydrogenase A (LDHA), pyruvate dehydrogenase kinase 4 (PDK4), and DNA-damage-inducible transcript 4 (DDIT4).

Not established in humans; engineered for improved metabolic stability and oral exposure relative to first-generation ERR agonists